Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lantheus Holdings Inc LNTH

Healthcare Medical Instruments & Supplies
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic... see more

Recent & Breaking News (NDAQ:LNTH)

Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI(TM) at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting

GlobeNewswire September 1, 2023

Lantheus to Present at the Wells Fargo Healthcare Conference

GlobeNewswire August 31, 2023

Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty

GlobeNewswire August 3, 2023

Lantheus Reports Second Quarter 2023 Financial Results

GlobeNewswire August 3, 2023

Lantheus to Host Second Quarter 2023 Earnings Conference Call and Webcast on August 3, 2023, at 8:00 a.m. Eastern Time

GlobeNewswire July 20, 2023

Lantheus Announces Presentations Featuring PYLARIFY AI(TM) at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

GlobeNewswire June 12, 2023

Lantheus to Present at the Jefferies Healthcare Conference

GlobeNewswire June 1, 2023

Lantheus Announces Payment to Contingent Value Rights (CVR) Holders of $99.7 million or $1.15 per CVR

GlobeNewswire May 23, 2023

Lantheus Reports First Quarter 2023 Financial Results

GlobeNewswire May 4, 2023

Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

GlobeNewswire April 24, 2023

Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

GlobeNewswire April 24, 2023

Lantheus to Host First Quarter 2023 Earnings Conference Call and Webcast on May 4, 2023, at 8:00 a.m. Eastern Time

GlobeNewswire April 20, 2023

POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

GlobeNewswire March 27, 2023

Lantheus Announces Two Key Executive Promotions

GlobeNewswire March 17, 2023

Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire February 23, 2023

Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels

GlobeNewswire February 16, 2023

Lantheus to Host Fourth Quarter and Full Year 2022 Earnings Conference Call and Webcast on February 23, 2023, at 8:00 a.m. Eastern Time

GlobeNewswire February 9, 2023

Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

GlobeNewswire February 8, 2023

Lantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer's Disease

GlobeNewswire February 6, 2023

POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH Trial

GlobeNewswire January 12, 2023